0001104659-20-107677 | 6-K | XBRL Viewer

Print Document View Excel Document

Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2020
Document and Entity Information
Entity Registrant Name	Centogene N.V.
Entity Central Index Key	0001757097
Document Type	6-K
Document Period End Date	Jun. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2

Unaudited interim condensed consolidated statements of comprehensive loss - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Unaudited interim condensed consolidated statements of comprehensive loss
Revenue	€ 9,719	€ 11,206	€ 21,824	€ 21,921
Cost of sales	6,815	6,114	13,833	12,858
Gross profit	2,904	5,092	7,991	9,063
Research and development expenses	3,119	2,407	5,810	4,108
General administrative expenses	7,767	5,693	15,665	11,603
Selling expenses	2,386	2,345	4,712	4,356
Other operating income	801	590	1,746	1,688
Other operating expenses	537	122	1,812	464
Real estate transfer tax expenses		1,200		1,200
Operating loss	(10,104)	(6,085)	(18,262)	(10,980)
Interest and similar income	13	4	13	12
Interest and similar expense	269	211	718	431
Financial costs, net	(256)	(207)	(705)	(419)
Loss before taxes	(10,360)	(6,292)	(18,967)	(11,399)
Income tax (benefits)/expenses		(11)	129	163
Loss for the period	(10,360)	(6,281)	(19,096)	(11,562)
Other comprehensive income/(loss), all attributable to equity holders of the parent	(6)	8	70	10
Total comprehensive loss	(10,366)	(6,273)	(19,026)	(11,552)
Attributable to:
Equity holders of the parent	(10,364)	(6,216)	(18,963)	(11,426)
Non-controlling interests	(2)	(57)	(63)	(126)
Total comprehensive loss	€ (10,366)	€ (6,273)	€ (19,026)	€ (11,552)
Loss per share-Basic and diluted	€ (0.52)	€ (0.39)	€ (0.95)	€ (0.72)

Unaudited interim condensed consolidated statements of financial position - EUR (€) € in Thousands	Jun. 30, 2020	Dec. 31, 2019
Non-current assets
Intangible assets	€ 16,452	€ 14,145
Property, plant and equipment	10,784	8,376
Right-of-use assets	24,750	24,932
Other assets	2,003	1,948
Non-current assets	53,989	49,401
Current assets
Inventories	8,061	1,809
Trade receivables and contract assets	14,983	16,593
Other assets	8,482	8,612
Cash and cash equivalents	17,400	41,095
Current assets	48,926	68,109
Total assets	102,915	117,510
Equity
Issued capital	2,383	2,383
Capital reserve	99,492	98,099
Retained earnings and other reserves	(60,340)	(40,622)
Non-controlling interest	(53)	(938)
Equity	41,482	58,922
Non-current liabilities
Non-current loans	567	1,578
Lease liabilities	18,948	18,069
Deferred tax liabilities	121
Government grants	9,575	9,941
Non-current liabilities	29,211	29,588
Current liabilities
Government grants	1,384	1,348
Current loans	4,367	3,688
Lease liabilities	3,411	3,635
Trade payables	8,828	8,554
Other liabilities	14,232	11,775
Current liabilities	32,222	29,000
Equity and liabilities	€ 102,915	€ 117,510

Unaduited interim condensed consolidated statements of cash flows - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Operating activities
Loss before taxes	€ (18,967)	€ (11,399)
Adjustments to reconcile earnings to cash flow from operating activities
Amortization and depreciation	4,432	2,849
Interest income	(13)	(12)
Interest expense	718	431
Expected credit loss allowances on trade receivables and contract assets	1,674	462
Sharebased payment expenses	1,393	4,828
Real estate transfer tax expenses		1,200
Other non-cash items	(557)	(147)
Changes in operating assets and liabilities:
Inventories	(6,252)	(360)
Trade receivables and contract assets	(64)	(2,556)
Other assets	269	(244)
Trade payables	274	2,095
Other liabilities	2,457	946
Cash flow used in operating activities	(14,636)	(1,907)
Investing activities
Cash paid for investments in intangible assets	(3,965)	(3,116)
Cash paid for investments in property, plant and equipment	(3,072)	(840)
Grants received for investment in property, plant and equipment	390	341
Interest received	13	12
Cash flow used in investing activities	(6,634)	(3,603)
Financing activities
Cash paid for acquisition of non-wholly owned subsidiary	(75)
Cash received from loans	928	1,828
Cash repayments of loans	(1,260)	(896)
Cash repayments of lease liabilities	(1,619)	(649)
Interest paid	(399)	(431)
Cash flow used in financing activities	(2,425)	(148)
Changes in cash and cash equivalents	(23,695)	(5,658)
Cash and cash equivalents at the beginning of the period	41,095	9,222
Cash and cash equivalents at the end of the period	€ 17,400	€ 3,564

Unaudited interim condensed consolidated statements of changes in equity - EUR (€) € in Thousands	Total	Issued capital	Capital reserve	Currency translation reserve	Retained earnings	Non-controlling interests	Total
Balance at beginning of the period at Dec. 31, 2018	€ 27,281	€ 1,903	€ 45,342	€ (16)	€ (19,948)	€ (757)	€ 26,524
Loss for the period	(11,436)				(11,436)	(126)	(11,562)
Other comprehensive loss	10			10			10
Total comprehensive loss	(11,426)			10	(11,436)	(126)	(11,552)
Share-based payments	488		488				488
Balance at end of the period at Jun. 30, 2019	16,343	1,903	45,830	(6)	(31,384)	(883)	15,460
Balance at beginning of the period at Dec. 31, 2019	59,860	2,383	98,099		(40,622)	(938)	58,922
Loss for the period	(19,033)				(19,033)	(63)	(19,096)
Other comprehensive loss	70			70			70
Total comprehensive loss	(18,963)			70	(19,033)	(63)	(19,026)
Share-based payments	1,393		1,393				1,393
Disposal of non-wholly owned subsidiary						268	268
Acquisition of non-wholly owned subsidiary	(755)				(755)	680	(75)
Balance at end of the period at Jun. 30, 2020	€ 41,535	€ 2,383	€ 99,492	€ 70	€ (60,410)	€ (53)	€ 41,482

- Definition

The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.

+ References + Details

- Definition

The amount of residual interest in the assets of the entity after deducting all its liabilities.

+ References + Details

- Definition

The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2019-01-01
-Paragraph 18
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2019-en-r&anchor=para_18_b&doctype=Standard
-URIDate 2019-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2019-01-01
-Paragraph 24
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2019-en-r&anchor=para_24_b&doctype=Standard
-URIDate 2019-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2019-01-01
-Paragraph 32
-Subparagraph a
-Clause ii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2019-en-r&anchor=para_32_a_ii&doctype=Standard
-URIDate 2019-03-27

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2019-01-01
-Paragraph 28
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2019-en-r&anchor=para_28_b&doctype=Standard
-URIDate 2019-03-27

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Note Effective on first application of IFRS 9
-Name IFRS
-Number 4
-IssueDate 2019-01-01
-Paragraph 39L
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2019-en-b&anchor=para_39L_e&doctype=Standard
-URIDate 2019-03-27

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2019-01-01
-Paragraph 23
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2019-en-r&anchor=para_23&doctype=Standard
-URIDate 2019-03-27

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2019-01-01
-Paragraph B10
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2019-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2019-03-27

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2019-01-01
-Paragraph 106
-Subparagraph d
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_106_d_i&doctype=Standard
-URIDate 2019-03-27

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Note Effective 2021-01-01
-Name IFRS
-Number 17
-IssueDate 2019-01-01
-Paragraph 113
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2019-en-r&anchor=para_113_b&doctype=Standard
-URIDate 2019-03-27

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2019-01-01
-Paragraph 81A
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_81A_a&doctype=Standard
-URIDate 2019-03-27

+ Details

General company information	6 Months Ended
General company information	Jun. 30, 2020
General company information
General company information	1 General company information Centogene N.V. (“the Company”) and its subsidiaries focus on rare diseases and seek to transform real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The mission of the Company is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our knowledge of the global rare disease market, including epidemiological and clinical data and innovative biomarkers. On November 7, 2019, the Company completed an initial public offering (“IPO”) and has since been listed on Nasdaq Global Market under stock code “CNTG”. We have historically conducted our business through Centogene AG (which is now known as Centogene GmbH), and therefore our historical financial statements present the results of operations and financial condition of Centogene AG and its controlled subsidiaries. In connection with our initial public offering, Centogene N.V. became the holding company of Centogene AG on November 12, 2019, and the historical consolidated financial statements of Centogene AG became the historical consolidated financial statements of Centogene N.V. Centogene N.V. is a public company with limited liability incorporated in the Netherlands, with registered office located at Am Strande 7 in 18055 Rostock, Germany and Dutch trade register number 72822872. On March 5, 2020, the Company resolved that Centogene AG shall be converted into a German limited liability company and renamed Centogene GmbH. Such conversion became effective upon the registration in the German commercial register on June 29, 2020. Unless otherwise stated, “Centogene GmbH” also refers to the historical operations of Centogene AG throughout the notes. In July 2020, the Company completed a follow-on public offering of 3,500,000 common shares of the Company (the “July 2020 Offering”), consisting of 2,000,000 common shares offered by the Company and 1,500,000 common shares offered by selling shareholders at a price to the public of USD 14.00 per common share (i.e. EUR 12.71 per share). Aggregate offering proceeds, net of underwriting discounts and commissions, were EUR 24 million to the Company and EUR 18 million to the selling shareholders.

Basis of preparation

6 Months Ended

Jun. 30, 2020

Basis of preparation

Basis of preparation

2 Basis of preparation

The interim condensed consolidated financial statements for the three and six months ended June 30, 2019 and 2020 have been prepared in accordance with IAS 34 Interim Financial Reporting.

The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group’s annual consolidated financial statements as of December 31, 2018 and 2019 and for the three years ended December 31, 2019. Unless otherwise specified, "the Company" refers to Centogene N.V. and Centogene GmbH throughout the remainder of these notes, while "the Group" refers to Centogene N.V., Centogene GmbH and its subsidiaries.

The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group’s annual consolidated financial statements for the year ended December 31, 2019, except for the adoption of new standards effective as of January 1, 2020 (see note 2.1). The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.

Several other amendments and interpretations apply for the first time in 2020, but do not have an impact on the interim condensed consolidated financial statements of the Group.

These interim condensed consolidated financial statements are presented in euro, which is the Group's functional currency. Unless otherwise specified, all financial information presented in euro is rounded to the nearest thousand (EUR k) in line with customary commercial practice.

2.1Effects of new accounting standards

The following amendments and interpretations apply for the first time in 2020 and had no impact on the condensed consolidated financial statements of the Group:

Amendments to IAS 1 and IAS 8: Definition of Material

Amendments to IFRS 3: Definition of a Business

Amendments to IFRS 7, IFRS 9 and IAS 39: Interest Rate Benchmark Reform

References to the Conceptual Framework for Financial Reporting issued on 29 March 2018

Effect of COVID-19 Pandemic	6 Months Ended
Effect of COVID-19 Pandemic	Jun. 30, 2020
Effect of COVID-19 Pandemic
Effect of COVID-19 Pandemic	3 Effect of COVID-19 Pandemic The COVID-19 pandemic, which began in December 2019, has spread worldwide and continues to cause many governments to maintain measures to slow the spread of the outbreak through quarantines, travel restrictions, closures of borders and requiring maintenance of physical distance between individuals. The Company has commenced testing for COVID-19 since the end of March 2020. Starting from the Mecklenburg-Western Pomerania region of Germany focusing on employees and essential workers in Rostock, the testing for COVID-19 was further expanded to nursing homes as well as to high school students in Germany, and made available to the rest of the world since May 2020. Some of the tests are offered free of charge by the Company, while others are offered in collaboration with the state government, educational institutions and other companies, as well as via the online marketplace. Revenues are based on a negotiated price per test or on the basis of agreements covering tests to be performed over defined periods. Given the short turnaround time for the COVID-19 tests, revenues from COVID-tests which are on a price per test basis are considered as recognized at a point in time. Revenues from COVID-19 tests which are on the basis of agreements covering tests to be performed over defined periods are considered as recognized over time. Revenues generated from the testing for COVID-19 for the three and six months ended June 30, 2020 amounted to EUR 2,082k and EUR 2,095k, respectively, and are included in the revenues of the diagnostics segment. Out of the total revenues from the testing for COVID-19, EUR 2,072k and EUR 2,085k were generated in Europe for the three and six months ended June 30, 2020, of which over 95% in Germany, which is the country of the registered office of the Company. Total direct costs incurred for the COVID-19 tests in the three and six months ended June 30, 2020 amounted to EUR 1,283k and EUR 1,360k, respectively, of which EUR 424k and EUR 483k, respectively, are related to the tests offered free of charge and are included accordingly in general administrative expenses and research and development expenses, as appropriate. To support the expansion of test offerings, the Company acquired laboratory facilities and equipment for a total consideration of EUR 1,800k and leased laboratory space in Hamburg, Germany, in April 2020. In July 2020, the Company further leased laboratory space in Frankfurt, Germany. Total investments in COVID-19 testing as of June 30, 2020 amounted to approximately EUR 2.5 million, of which approximately EUR 1.9 million and EUR 0.6 million, respectively, are included in property plant and equipment and right-of-use assets.

Revenues from contracts with customers

6 Months Ended

Jun. 30, 2020

Revenues from contracts with customers

Revenues from contracts with customers

4 Revenues from contracts with customers

Three months ended June 30


in EUR k	Three months ended June 30, 2019
	Pharmaceutical	Diagnostics	Total
Rendering of services	4,227	6,638	10,865
Sales of goods	341	—	341
Total Revenues from contracts with external customers	4,568	6,638	11,206

Recognized over time	3,996	6,638	10,634
Recognized at a point in time	572	—	572
Total Revenues from contracts with external customers	4,568	6,638	11,206

Geographical information
Europe	247	1,883	2,130
—Germany*	195	71	266
Middle East	29	3,189	3,218
—Saudi Arabia#	—	1,495	1,495
North America	4,292	644	4,936
—United States#	4,292	564	4,856
Latin America	—	681	681
Asia Pacific	—	241	241
Total Revenues from contracts with external customers	4,568	6,638	11,206

* country of the incorporation of Centogene GmbH

# countries contributing more than 10% of the Group’s total consolidated revenues for the three months ended June 30, 2019


in EUR k	Three months ended June 30, 2020
	Pharmaceutical	Diagnostics	Total
Rendering of services	3,606	5,737	9,343
Sales of goods	334	42	376
Total Revenues from contracts with external customers	3,940	5,779	9,719

Recognized over time	3,606	4,206	7,812
Recognized at a point in time	334	1,573	1,907
Total Revenues from contracts with external customers	3,940	5,779	9,719

Geographical information
Europe	23	3,204	3,226
—Germany*	19	2,096	2,115
—Netherlands**	—	—	—
Middle East	45	1,789	1,834
—Saudi Arabia#	—	1,106	1,106
North America	3,872	501	4,374
—United States#	3,872	493	4,365
Latin America	—	219	219
Asia Pacific	—	66	66
Total Revenues from contracts with external customers	3,940	5,779	9,719

* country of the incorporation of Centogene GmbH

** country of the incorporation of Centogene N.V.

# countries contributing more than 10% of the Group’s total consolidated revenues for the three months ended June 30, 2020

Six months ended June 30


in EUR k	Six months ended June 30, 2019
	Pharmaceutical	Diagnostics	Total
Rendering of services	8,033	13,223	21,256
Sales of goods	665	—	665
Total Revenues from contracts with external customers	8,698	13,223	21,921

Recognized over time	7,452	13,223	20,675
Recognized at a point in time	1,246	—	1,246
Total Revenues from contracts with external customers	8,698	13,223	21,921

Geographical information
Europe	280	3,411	3,691
—Germany*	195	133	328
Middle East	61	6,711	6,772
—Saudi Arabia#	—	3,182	3,182
North America	8,357	1,321	9,678
—United States#	8,357	972	9,329
Latin America	—	1,319	1,319
Asia Pacific	—	461	461
Total Revenues from contracts with external customers	8,698	13,223	21,921

*country of the incorporation of Centogene GmbH

# countries contributing more than 10% of the Group's total consolidated revenues for the six months ended June 30, 2019


in EUR k	Six months ended June 30, 2020
	Pharmaceutical	Diagnostics	Total
Rendering of services	7,880	13,292	21,172
Sales of goods	610	42	652
Total Revenues from contracts with external customers	8,490	13,334	21,824

Recognized over time	7,880	11,761	19,641
Recognized at a point in time	610	1,573	2,183
Total Revenues from contracts with external customers	8,490	13,334	21,824

Geographical information
Europe	67	4,820	4,887
—Germany*	38	2,169	2,207
—Netherlands**	—	3	3
Middle East	48	6,204	6,252
—Saudi Arabia#	—	4,139	4,139
North America	8,375	1,122	9,497
—United States#	8,375	964	9,339
Latin America	—	965	965
Asia Pacific	—	223	223
Total Revenues from contracts with external customers	8,490	13,334	21,824

* country of the incorporation of Centogene GmbH

** country of the incorporation of Centogene N.V.

# countries contributing more than 10% of the Group's total consolidated revenues for the six months ended June 30, 2020

The Group collaborated with the majority of our pharmaceutical partners on a worldwide basis in 2019 and 2020. In addition, in cases where our pharmaceutical partners are developing a new rare disease treatment, it is generally anticipated that the final approved treatment will be made available globally. As a result, we allocate the revenues of our pharmaceutical segment by geographical region by reference to the location where each pharmaceutical partner mainly operates, which is based on the region from which most of their revenues are generated. The allocation of revenues in our diagnostics segment is based on the location of each customer.

Pharmaceutial segment

During the three and six months ended June 30, 2020, revenues from one pharmaceutical partner represented 26.2% and 26.4% respectively, of the Group's total revenues (the three and six months ended June 30, 2019: 26.7% and 27.1%, respectively).

During the three and six months ended June 30, 2019, we have entered into two collaborations with an existing pharmaceutical partner, of which upfront fees totaling EUR 80k and EUR 430k, respectively, representing the transaction price allocated to the one-off transfer of the Group's intellectual property were received and recognized as revenues. No such revenues were recognized in the three and six months ended June 30, 2020.

The Group recognized impairment losses on receivables and contract assets arising from contracts with customers, included under Other operating expenses in the consolidated statement of comprehensive loss, amounting to EUR 500k and EUR 1,674k, respectively, for the three and six months ended June 30, 2020 (the three and six months ended June 30, 2019: EUR 122k and EUR 462k, respectively).

Segment information

6 Months Ended

Jun. 30, 2020

Segment information

Segment information

5 Segment information

Three months ended June 30


in EUR k	Three months ended June 30, 2019
	Pharmaceutical	Diagnostics	Corporate	Total
Total Revenues from contracts with external customers	4,568	6,638	—	11,206

Adjusted EBITDA	3,217	530	(6,185)	(2,438)

Capital Expenditures
Additions to property, plant and equipment and right-of-use assets	172	227	—	399
Additions to intangible assets	1,018	—	985	2,003

Other segment information
Depreciation and amortization	257	561	635	1,453
Research and development expenses	—	—	2,407	2,407


in EUR k	Three months ended June 30, 2020
	Pharmaceutical	Diagnostics	Corporate	Total
Total Revenues from contracts with external customers	3,940	5,779	—	9,719

Adjusted EBITDA	1,799	(824)	(8,395)	(7,420)

Capital Expenditures
Additions to property, plant and equipment and right-of-use assets	301	2,073	1,249	3,623
Additions to intangible assets	1,852	—	922	2,774

Other segment information
Depreciation and amortization	389	617	1,342	2,348
Research and development expenses	—	—	3,119	3,119

Six months ended June 30


	Six months ended June 30, 2019
in EUR k	Pharmaceutical	Diagnostics	Corporate	Total
Total Revenues from contracts with external customers	8,698	13,223	—	21,921

Adjusted EBITDA	6,161	541	(10,005)	(3,303)

Capital Expenditures
Additions to property, plant and equipment and right-of-use assets	179	247	414	840
Additions to intangible assets	1,786	—	1,330	3,116

Other segment information
Depreciation and amortization	513	1,085	1,252	2,849
Research and development expenses	—	—	4,108	4,108


	Six months ended June 30, 2020
in EUR k	Pharmaceutical	Diagnostics	Corporate	Total
Total Revenues from contracts with external customers	8,490	13,334	—	21,824

Adjusted EBITDA	4,407	(737)	(16,107)	(12,437)

Capital Expenditures
Additions to property, plant and equipment and right-of-use assets	301	2,890	1,836	5,027
Additions to intangible assets	2,854	—	1,111	3,965

Other segment information
Depreciation and amortization	1,071	1,161	2,200	4,432
Research and development expenses	—	—	5,810	5,810

Adjustments

Corporate expenses, depreciation and amortization, interest and similar income and expenses, as well as share-based payment expenses are not allocated to individual segments as the underlying instruments are managed on a group basis. Current taxes and deferred taxes are allocated to Corporate as they are also managed on a group basis.

Increases in corporate expenses for the three and six months ended June 30, 2020 are mainly due to our continued international growth and business expansion. The increase is also due to the costs of operating as a public company, such as additional legal, accounting, corporate governance and investor relations expenses, and higher directors' and officers' insurance premiums.

Corporate expenses for the three and six months ended June 30, 2020 included expenses related to the July 2020 Offering as described in note 1 of EUR 173k and EUR 173k, respectively, while corporate expenses for the three and six months ended June 30, 2019 included expenses incurred in relation to the IPO as described in note 1 of EUR 109k and EUR 318k, respectively (included in General Administrative Expenses). Corporate expenses for the three and six months ended June 30, 2019 also included real estate transfer tax of EUR 1,200k related to an intercompany sale of land and building. No such expenses were incurred in the six months ended June 30, 2020 (see note 7).

Capital expenditure consists of additions of property, plant and equipment, right-of-use assets and intangible assets. All of such assets are located in Germany, which is the country of the registered office of the Company, except for property, plant and equipment of EUR 368k (December 31, 2019: EUR 286k) and right-of-use assets of EUR 876k (December 31, 2019: EUR 1,042k), which is located in the United States.

Reconciliation of segment Adjusted EBITDA to Group loss for the period


For the three months ended June 30	2019	2020
Reported segment Adjusted EBITDA	3,747	975
Corporate expenses	(6,185)	(8,395)
	(2,438)	(7,420)
Share-based payment expenses	(2,195)	(336)
Depreciation and amortization	(1,453)	(2,348)
Operating loss	(6,085)	(10,104)
Financial costs, net	(207)	(256)
Income taxes benefit	11	—
Loss for the three months ended June 30	(6,281)	(10,360)


For the six months ended June 30	2019	2020
Reported segment Adjusted EBITDA	6,702	3,670
Corporate expenses	(10,005)	(16,107)
	(3,303)	(12,437)
Share-based payment expenses	(4,828)	(1,393)
Depreciation and amortization	(2,849)	(4,432)
Operating loss	(10,980)	(18,262)
Financial costs, net	(419)	(705)
Income taxes expenses	(163)	(129)
Loss for the six months ended June 30	(11,562)	(19,096)

Other income and expenses

6 Months Ended

Jun. 30, 2020

Other income and expenses

Other income and expenses

6 Other income and expenses

6.1Other operating income


	For the three months ended June 30		For the six months ended June 30
in EUR k	2019	2020	2019	2020
Government grants	503	703	1,470	1,405
Income from the reversal of provisions	—	—	89	—
Others	87	98	129	341
Total other operating income	590	801	1,688	1,746

Government grants contain performance-based grants to subsidize research, development and innovation in the state of Mecklenburg-Western Pomerania from funds granted by the European Regional Development Fund. Furthermore, government grants contain the release of deferred income from investment related grants.

6.2Other operating expenses


	For the three months ended June 30		For the six months ended June 30
in EUR k	2019	2020	2019	2020
Currency losses	—	37	2	37
Expected credit loss allowances on trade receivables	122	500	462	1,674
Others	—	—	—	101
Total other operating expenses	122	537	464	1,812

Considering the impact of the COVID-19 pandemic on the global economy and the unforeseeable potential magnitude of the ultimate disruptions to different businesses, the Group has taken such new developments into consideration when assessing its credit risk, in particular regarding the MENA region for the diagnostic segment as it represents the majority of that segment's revenue. Such assessment resulted in the recognition of additional credit losses of EUR 500k and EUR 1,674k, respectively, for the three and six months ended June 30, 2020 (for the three and six months ended June 30, 2019: EUR 122k and EUR 462k, respectively,). See also note 8.

During the six months ended June 30, 2020, the Group disposed of its entire 51% interest in LPC GmbH (“LPC”) to the minority shareholders for a consideration of EUR 213k, of which EUR 200k is to be paid over a period of four years (and included in other assets, see note 8). The related non-controlling interest of EUR 268k (accumulated share of loss) was debited to profit or loss, and the sale resulted in a loss of EUR 101k.

Sale and Leaseback transaction	6 Months Ended
Sale and Leaseback transaction	Jun. 30, 2020
Sale and Leaseback transaction
Sale and Leaseback transaction	7 Sale and Leaseback transaction In June 2019, in preparation for a sale and leaseback transaction, the Company sold its land and building (the Rostock headquarters building) with a carrying value of EUR 22,778k to another subsidiary of the Group. Such intercompany transaction resulted in a real estate transfer tax expense of EUR 1,200k and was recognized in the three and six months period ended June 30, 2019.

Trade receivables and contract assets and other assets

6 Months Ended

Jun. 30, 2020

Trade receivables and contract assets and other assets

Trade receivables and contract assets and other assets

8 Trade receivables and contract assets and other assets


in EUR k	Dec 31, 2019	Jun 30, 2020
Non‑current
Other assets - Rental deposits	1,948	1,853
Other assets – Others	-	150
	1,948	2,003
Current
Trade receivables, net	12,709	12,473
Contract assets, net	3,884	2,510
Receivables due from shareholders	2,766	2,766
Other assets	5,846	5,716
	25,205	23,465
Total non-current and current trade receivables and contract assets and other assets	27,153	25,468

Trade receivables and contract assets

Trade receivables are non-interest bearing and are generally due in 30 to 90 days. In general, portfolio-based expected credit loss allowances are recognized on trade receivables and contract assets.

Considering the potential impact of the COVID-19 pandemic on the global economy, the Group has re-assessed the credit loss rates in relation to the outstanding trade receivables and contract assets as follows:


in EUR k	Dec 31, 2019		Jun 30, 2020
Not past due	11,102		10,340
Past due 1-30 days	1,113		1,159
Past due 31-90 days	1,708		1,508
Past due more than 90 days	5,005		5,985
Total Gross amount of trade receivables and contract assets	18,928		18,992

Expected credit loss rate
Not past due	0.3	%	0.6	%
Past due 1-30 days	1.0	%	5.7	%
Past due 31-90 days	1.2	%	7.6	%
Past due more than 90 days	45.4	%	62.9	%
Expected credit loss rate on total gross trade receivables and contract assets	12.3	%	21.3	%

Expected credit loss	2,335		4,009

Receivables due from shareholders

In 2016, the Group established a virtual share option program ("2016 VSOP") under Centogene GmbH that entitled the management board to grant virtual share options to individuals, in regard to services they provide and their continuous commitment to the Group. Upon completion of the IPO in November 2019, all options granted under the 2016 VSOP were vested immediately in full, and the holders of vested options were entitled to receive a direct cash payment from the Company according to the calculation as stipulated in the 2016 VSOP, which is determined based on the IPO price of the shares of Centogene N.V. and the exercise prices of the vested options.

The payables by the Group to the holders of vested options were recorded as a liability with a carrying amount of EUR 2,766k (December 31, 2019: EUR 2,766k) (see note 11.2).

As the payments to the option holders would be reimbursed by certain original shareholders to the Company, corresponding receivables against shareholders were recorded. Such receivables were considered as additional capital from shareholders and recorded against equity (capital reserve). Upon the completion of the July 2020 Offering, the relevant payables to the holders of vested options were settled by the proceeds received from such original shareholders from the sale of their shares.

Other assets

The non-current portion of other assets mainly include cash deposit of EUR 1,500k (used to secure a bank guarantee of EUR 3,000k) relating to the leases of Rostock headquarters building, cash deposits of EUR 128k (used to secure a bank guarantee of EUR 257k) relating to the leases of Berlin office and EUR 191k for the leases of certain plant and machineries. It also includes the consideration receivable for the sale of LPC of EUR 213k, among which EUR 150k is due after 1 year (see note 6.2).

The current portion of other assets also include VAT receivables of EUR 1,124k (December 31, 2019: EUR 1,311k), prepaid expenses of EUR 2,150k (December 31, 2019: EUR 3,481k) as well as receivables from grants of EUR 1,068k (December 31, 2019: EUR 409k).

Other assets also include costs relating to the July 2020 Offering of EUR 552k (December 31, 2019: EUR nil) which will be offset against capital reserve upon completion of the transaction in July 2020.

Cash and short-term deposits	6 Months Ended
Cash and short-term deposits	Jun. 30, 2020
Cash and short-term deposits
Cash and short term deposits	9 Cash and short‑term deposits As of June 30, 2020, the Group has pledged its short-term deposits with carrying amount of EUR 1,500k (December 31, 2019: EUR 1,500k) and EUR 2,500k (December 31, 2019: EUR 2,500k) respectively, to fulfil collateral requirements in respect of existing secured bank loan and overdraft facility up to EUR 2,500k. In addition, the Group has pledged its short-term deposits of EUR 500k (December 31, 2019: EUR nil) related to another overdraft facility up to EUR 500k. The restriction applying to the collateral may be terminated at any time subject to the full amount of the relevant bank loans and the overdrafts being repaid.

Equity	6 Months Ended
Equity	Jun. 30, 2020
Equity.
Equity	10 Equity As discussed in note 1, Centogene N.V. became the parent holding company of the Group on November 12, 2019 as part of the IPO process. All share, per-share and related information presented in the financial statements and corresponding disclosure notes have been retrospectively adjusted, where applicable, to reflect the impact of the share split resulting from the reorganization. Capital reserve As of June 30, 2020, capital reserve included a share premium of EUR 90,297k, being amounts contributed by shareholders at the issuance of shares in excess of the par value of the shares issued, net of any transaction costs incurred for the share issuance. In addition, it also included amounts recorded in respect of share-based payments. For additional information on the share-based payments, see note 12.

Financial liabilities

6 Months Ended

Jun. 30, 2020

Financial liabilities

Financial liabilities

11 Financial liabilities

11.1Interest-bearing liabilities


in EUR k	Dec 31, 2019	Jun 30, 2020
Non‑current liabilities
Non‑current portion of secured bank loans	968	567
Municipal loans	610	—
Total non‑current loans	1,578	567
Lease liabilities	18,069	18,948
Total non‑current liabilities	19,647	19,515

Current liabilities
Current portion of secured bank loans	802	802
Other bank loans	—	438
Bank overdrafts	2,636	3,127
Municipal loans	250	—
Total current loans	3,688	4,367
Current portion of lease liabilities	3,635	3,411
Total current liabilities	7,323	7,778

Total non‑current and current liabilities	26,970	27,293

As of June 30, 2020, short-term cash deposits of EUR 1,500k (December 31, 2019: EUR 1,500k) were used to secure the secured bank loan outstanding (see note 9).

Other bank loans outstanding as of June 30, 2020 represented bank loans granted under the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) which was enacted in March 2020 in the United States, which was a stimulus bill intended to, among other things, bolster, among other things, the U.S. economy, and provide assistance to qualifying businesses and individuals. The CARES Act included an infusion of funds into the healthcare system. The loans were to be used for payment of payroll to employees in the United States, as well as rent and other utility payment obligations. Subject to certain reporting and review requirements, the Company may apply for forgiveness of the amount during the 8-week period beginning on the date of first disbursement of the loans. The Company is in the process of preparing the relevant application and anticipates the result of the forgiveness will be available in 2020. The amount which is forgiven will be considered as government grant income, while any remaining amount not forgiven will be repaid by the Company. Accordingly, the entire amount was classified as current.

The following table is based on the original terms and conditions:

Conditions and statement of liabilities

The outstanding interest-bearing liabilities as of June 30, 2020 and December 31, 2019 have the following conditions:


					Dec 31, 2019		Jun 30, 2020
		Nominal			Nominal	Carrying	Nominal	Carrying
in EUR k	Currency	interest rate		Maturity	amount	amount	amount	amount
Secured bank loan	EUR	3.95	%	2018‑25	1,770	1,770	1,369	1,369
Other bank loan	USD	1	%	2020-22	—	—	438	438
Municipal loan	EUR	8.25%; plus 1.5% profit-related; 0.75% on losses		2018-23	500	500	—	—
Municipal loan	EUR	8%; plus 1.5% profit-related; 0.75% on losses		2021	360	360	—	—
Bank overdrafts	EUR	4.46	%	2022	476	476	478	478
Bank overdrafts	EUR	3.75	%	Rollover	2,160	2,160	2,346	2,346
Bank overdrafts	EUR	3.59	%	Rollover	—	—	303	303
Lease liabilities	EUR	2.1%-3.5%*, 5.4%-8.9%		2017-31	21,704	21,704	22,359	22,359
Total interest‑bearing financial liabilities					26,970	26,970	27,293	27,293

* represents the incremental borrowing rate of the Group at the commencement of the leases

The bank overdrafts of EUR 2,346k as of June 30, 2020 (December 31, 2019: EUR 2,160k) were secured by short-term deposits with a carrying amount of EUR 2,500k (December 31, 2019: EUR 2,500k) (see note 9). The bank overdrafts of EUR 478k (December 31, 2019: EUR 476k) were secured by guarantees provided by certain of the Company's shareholders as of December 31, 2019, and were released providing security over a short-term deposit with a carrying amount of EUR 500k subsequent to the year end (see note 9).

The municipal loan due to MBMV (Mittelständische Bürgschaftsbank Mecklenburg-Vorpommern) of EUR 860k outstanding as of December 31, 2019 was secured by guarantees provided by the Group's shareholders, and were released upon full repayment in February 2020.

11.2Trade payables and other liabilities


in EUR k	Dec 31, 2019	Jun 30, 2020
Trade payables	8,554	8,828
Government grants (deferred income)	11,289	10,959
Liability for Virtual Stock Option Program	2,769	2,766
Contract liabilities	3,748	3,800
Others	5,258	7,666
Trade payables and other liabilities	31,618	34,019
Non‑current	9,941	9,575
Current	21,677	24,444

Government grants mainly include investment-related government grants. These were received for the purchase of certain items of property, plant and equipment for the research and development facilities in Mecklenburg-Western Pomerania, including the Rostock facility. The grants were issued in the form of investment subsidies as part of the joint federal and state program, "Verbesserung der regionalen Wirtschaftsstruktur" (improvement of the regional economic structure) in connection with funds from the European Regional Development Fund. Additional grants received during the six months ended June 30, 2020 are related to the purchase of certain items of property, plant and equipment amounted to EUR 390k (the six months ended June 30, 2019: EUR 341k).

In addition, other liabilities include personnel-related liabilities for vacation and bonuses totaling EUR 2,907k (December 31, 2019: EUR 2,264k) as well as liabilities for wage and church tax of EUR 527k (December 31, 2019: EUR 376k). Other liabilities as of June 30, 2020 include costs related to the July 2020 Offering of EUR 725k, while other liabilities as of December 31, 2019 included costs relating to the IPO of EUR 565k.

Share-based payments	6 Months Ended
Share-based payments	Jun. 30, 2020
Share-based payments
Share-based payments	12 Share‑based payments At June 30, 2020 the Group had the following share‑based payment arrangements. (i) Equity share option - Replacement (ESOP 2017) In 2017, the Group established a second virtual share option program ("2017 VSOP”) that entitled the management board to grant virtual share options to individuals, in regard to services they provide and their continuous commitment to the Group. In connection with the IPO (see note 1), a transfer agreement was entered into between the holders of the 2017 VSOP, Centogene GmbH and the Company in November 2019, under which the 2017 VSOP was terminated, and the option holders were granted new share options of Centogene N.V. (“ESOP 2017”). The number of options granted to each holder under ESOP 2017 was based on the number of options granted to them under 2017 VSOP and the IPO price of Centogene N.V. Accordingly, 805,308 new share options were granted pursuant to Centogene N.V’s long-term incentive plan (the “Long-term Incentive Plan”), with each option representing one common share of Centogene N.V., and an exercise price equal to the nominal value of the share of Centogene N.V., which is EUR 0.12. The options were considered vested upon the completion of the IPO, but were not exercisable in the first 180 days subsequent to the listing (lock-up period). The contractual life for the share options as at June 30, 2020 is 9.5 years (December 31, 2019: 10 years). The share options issued under ESOP 2017 are equity-settled and the fair value of the options were fully recognized in equity under capital reserve on the date of grant. (ii) Equity share option 2019 (ESOP 2019) In 2019, an agreement was entered into between the Company and an individual of the Supervisory Board. According to this agreement, a total of 396,522 options, each option representing one common share, were granted pursuant to the Long-term Incentive Plan to the individual Supervisory Board member with exercise price equaling to the IPO price, which is EUR 12.58 per option, on the date of the IPO of the Company. The vesting period shall be three years commencing on the day of grant, where one-third of the granted options shall be vested at the end of each year of grant, and the first year ending on March 31, 2020. The contractual life for the share options as at December 31, 2019 is ten years and the weighted average fair value of options outstanding was EUR 9.08. The share options issued under “ESOP 2019” will be equity-settled and the fair value of the options were recognized in equity under capital reserve, based on the fair value on the date of grant, and will be charged to profit or loss over the vesting period by using the graded vested approach. For the three and six months ended June 30, 2020, the Group recognized EUR 336k and EUR 1,393k repectively, of share-based payment expense in the statement of comprehensive income. For the six months ended June 30, 2019, the Group recognized EUR 4,828k of share-based payment expense in the statement of comprehensive income in relation to the cash-settled virtual share option programs of Centogene GmbH, which were cancelled upon completion of IPO.

Commitments	6 Months Ended
Commitments	Jun. 30, 2020
Commitments
Commitments	13 Commitments Future payments for non-cancellable leases The Group has various lease contracts in relation to the expansion of the Rostock headquarters and leasing of the Frankfurt laboratory that have not yet commenced as at June 30, 2020. The future lease payments and utilities for these non-cancellable lease contracts are EUR 32k within one year, EUR 1,218k within five years and EUR 5,324k thereafter. The Group has various non-cancellable lease contracts of office equipment and storage spaces which had a lease term of less than 12 months or were related to leases of low-value assets, and therefore the short-term lease recognition exemption was applied to these contracts. The future lease payments for these non-cancellable lease contracts are EUR 75k within one year (December 31,2019: EUR 72k) and EUR 23k within five years (December 31, 2019: EUR 36k). Future payment obligations As of June 30, 2020, the Group concluded agreements with suppliers, for goods and services to be provided subsequent to June 30, 2020 with a total payment obligation of approximately EUR 6,172k (December 31, 2019: EUR 802k).

Contingent Liabilities	6 Months Ended
Contingent Liabilities	Jun. 30, 2020
Contingent Liabilities
Contingent Liabilities	14 Contingent Liabilities In May 2016, the Company was informed in writing by the Universitair Medisch Centrum Utrecht (‘‘UMCU’’) that a claim had been initiated against UMCU regarding a prenatal diagnostic test that the Company conducted at their request which failed to identify a specific mutation present in a patient. On November 8, 2018, the UMCU and Neon Underwriting Limited formally filed a legal claim in the local court in Rostock, Germany against the Company alleging that the Company’s negligence in performing the test resulted in the misdiagnosis of the patient. UMCU is seeking recovery for compensatory damages as a result of the alleged misdiagnosis. By court order of November 8, 2018 the Regional Court of Rostock set the amount in dispute at EUR 880k. On November 12, 2018, the Company submitted a notice to the Regional Court of Rostock of the intention to defend against the claim. On January 3, 2019, the Company filed a motion to dismiss in which the Company denied the merits of the claim. UMCU and Neon Underwriting Limited responded to this motion on March 15, 2019 with a statement of reply, and the parties made several court filings setting out their arguments since. By order dated June 3, 2019, the Regional Court of Rostock provided a first set of questions to be answered by an expert witness. Following a request by the Court, the Director of the Institute of Genetics at the University of Bonn recommended a professor for human genetics from the University of Aachen be appointed as an expert witness in this case. The Company agreed to such recommendation. During the 3 months ended June 30, 2020, the dispute amount was increased to EUR 1.3 million. The claim was assigned to a new judge, due to an illness of the preceding judge, while the decision to appoint the recommended expert witness has not yet been finalized. The Company intends to continue to rigorously defend its position and considers that it is not probable the legal claim towards the Company will be successful and as a result has not recognized a provision for this claim as of June 30, 2020. In addition, in case a settlement would be required, the Company believes that the corresponding liability will be fully covered by the respective existing insurance policies.

Subsequent Event	6 Months Ended
Subsequent Event	Jun. 30, 2020
Subsequent Event
Subsequent Event	15 Subsequent Event July 2020 Offering On July 14, 2020, the Company completed a follow-on offering of 3,500,000 common shares of the Company, consisting of 2,000,000 common shares offered by the Company and 1,500,000 common shares offered by selling shareholders at a price to the public of USD 14.00 per common share (i.e. EUR 12.71 per share). Aggregate offering proceeds, net of underwriting discounts and commissions, were EUR 24 million to the Company and EUR 18 million to the selling shareholders. Upon the completion of the offering, proceeds to certain selling holders, who are also the shareholders backing 2016 VSOP under Centogene GmbH, were received by the Company, which were then used to settle the payables to the vested option holders in July 2020. These unaudited interim condensed consolidated financial statements were approved by management on September 23, 2020.

Revenues from contracts with customers (Tables)

6 Months Ended

Jun. 30, 2020

Revenues from contracts with customers

Schedule of geographical information


in EUR k	Three months ended June 30, 2019
	Pharmaceutical	Diagnostics	Total
Rendering of services	4,227	6,638	10,865
Sales of goods	341	—	341
Total Revenues from contracts with external customers	4,568	6,638	11,206

Recognized over time	3,996	6,638	10,634
Recognized at a point in time	572	—	572
Total Revenues from contracts with external customers	4,568	6,638	11,206

Geographical information
Europe	247	1,883	2,130
—Germany*	195	71	266
Middle East	29	3,189	3,218
—Saudi Arabia#	—	1,495	1,495
North America	4,292	644	4,936
—United States#	4,292	564	4,856
Latin America	—	681	681
Asia Pacific	—	241	241
Total Revenues from contracts with external customers	4,568	6,638	11,206

* country of the incorporation of Centogene GmbH

# countries contributing more than 10% of the Group’s total consolidated revenues for the three months ended June 30, 2019


in EUR k	Three months ended June 30, 2020
	Pharmaceutical	Diagnostics	Total
Rendering of services	3,606	5,737	9,343
Sales of goods	334	42	376
Total Revenues from contracts with external customers	3,940	5,779	9,719

Recognized over time	3,606	4,206	7,812
Recognized at a point in time	334	1,573	1,907
Total Revenues from contracts with external customers	3,940	5,779	9,719

Geographical information
Europe	23	3,204	3,226
—Germany*	19	2,096	2,115
—Netherlands**	—	—	—
Middle East	45	1,789	1,834
—Saudi Arabia#	—	1,106	1,106
North America	3,872	501	4,374
—United States#	3,872	493	4,365
Latin America	—	219	219
Asia Pacific	—	66	66
Total Revenues from contracts with external customers	3,940	5,779	9,719

* country of the incorporation of Centogene GmbH

** country of the incorporation of Centogene N.V.

# countries contributing more than 10% of the Group’s total consolidated revenues for the three months ended June 30, 2020

Six months ended June 30


in EUR k	Six months ended June 30, 2019
	Pharmaceutical	Diagnostics	Total
Rendering of services	8,033	13,223	21,256
Sales of goods	665	—	665
Total Revenues from contracts with external customers	8,698	13,223	21,921

Recognized over time	7,452	13,223	20,675
Recognized at a point in time	1,246	—	1,246
Total Revenues from contracts with external customers	8,698	13,223	21,921

Geographical information
Europe	280	3,411	3,691
—Germany*	195	133	328
Middle East	61	6,711	6,772
—Saudi Arabia#	—	3,182	3,182
North America	8,357	1,321	9,678
—United States#	8,357	972	9,329
Latin America	—	1,319	1,319
Asia Pacific	—	461	461
Total Revenues from contracts with external customers	8,698	13,223	21,921

*country of the incorporation of Centogene GmbH

# countries contributing more than 10% of the Group's total consolidated revenues for the six months ended June 30, 2019


in EUR k	Six months ended June 30, 2020
	Pharmaceutical	Diagnostics	Total
Rendering of services	7,880	13,292	21,172
Sales of goods	610	42	652
Total Revenues from contracts with external customers	8,490	13,334	21,824

Recognized over time	7,880	11,761	19,641
Recognized at a point in time	610	1,573	2,183
Total Revenues from contracts with external customers	8,490	13,334	21,824

Geographical information
Europe	67	4,820	4,887
—Germany*	38	2,169	2,207
—Netherlands**	—	3	3
Middle East	48	6,204	6,252
—Saudi Arabia#	—	4,139	4,139
North America	8,375	1,122	9,497
—United States#	8,375	964	9,339
Latin America	—	965	965
Asia Pacific	—	223	223
Total Revenues from contracts with external customers	8,490	13,334	21,824

* country of the incorporation of Centogene GmbH

** country of the incorporation of Centogene N.V.

# countries contributing more than 10% of the Group's total consolidated revenues for the six months ended June 30, 2020

Segment information (Tables)

6 Months Ended

Jun. 30, 2020

Segment information

Schedule of segment information and reconciliation of segment adjusted EBITDA to group loss for the period

Three months ended June 30


in EUR k	Three months ended June 30, 2019
	Pharmaceutical	Diagnostics	Corporate	Total
Total Revenues from contracts with external customers	4,568	6,638	—	11,206

Adjusted EBITDA	3,217	530	(6,185)	(2,438)

Capital Expenditures
Additions to property, plant and equipment and right-of-use assets	172	227	—	399
Additions to intangible assets	1,018	—	985	2,003

Other segment information
Depreciation and amortization	257	561	635	1,453
Research and development expenses	—	—	2,407	2,407


in EUR k	Three months ended June 30, 2020
	Pharmaceutical	Diagnostics	Corporate	Total
Total Revenues from contracts with external customers	3,940	5,779	—	9,719

Adjusted EBITDA	1,799	(824)	(8,395)	(7,420)

Capital Expenditures
Additions to property, plant and equipment and right-of-use assets	301	2,073	1,249	3,623
Additions to intangible assets	1,852	—	922	2,774

Other segment information
Depreciation and amortization	389	617	1,342	2,348
Research and development expenses	—	—	3,119	3,119

Six months ended June 30


	Six months ended June 30, 2019
in EUR k	Pharmaceutical	Diagnostics	Corporate	Total
Total Revenues from contracts with external customers	8,698	13,223	—	21,921

Adjusted EBITDA	6,161	541	(10,005)	(3,303)

Capital Expenditures
Additions to property, plant and equipment and right-of-use assets	179	247	414	840
Additions to intangible assets	1,786	—	1,330	3,116

Other segment information
Depreciation and amortization	513	1,085	1,252	2,849
Research and development expenses	—	—	4,108	4,108


	Six months ended June 30, 2020
in EUR k	Pharmaceutical	Diagnostics	Corporate	Total
Total Revenues from contracts with external customers	8,490	13,334	—	21,824

Adjusted EBITDA	4,407	(737)	(16,107)	(12,437)

Capital Expenditures
Additions to property, plant and equipment and right-of-use assets	301	2,890	1,836	5,027
Additions to intangible assets	2,854	—	1,111	3,965

Other segment information
Depreciation and amortization	1,071	1,161	2,200	4,432
Research and development expenses	—	—	5,810	5,810

Reconciliation of segment Adjusted EBITDA to Group loss for the period


For the three months ended June 30	2019	2020
Reported segment Adjusted EBITDA	3,747	975
Corporate expenses	(6,185)	(8,395)
	(2,438)	(7,420)
Share-based payment expenses	(2,195)	(336)
Depreciation and amortization	(1,453)	(2,348)
Operating loss	(6,085)	(10,104)
Financial costs, net	(207)	(256)
Income taxes benefit	11	—
Loss for the three months ended June 30	(6,281)	(10,360)


For the six months ended June 30	2019	2020
Reported segment Adjusted EBITDA	6,702	3,670
Corporate expenses	(10,005)	(16,107)
	(3,303)	(12,437)
Share-based payment expenses	(4,828)	(1,393)
Depreciation and amortization	(2,849)	(4,432)
Operating loss	(10,980)	(18,262)
Financial costs, net	(419)	(705)
Income taxes expenses	(163)	(129)
Loss for the six months ended June 30	(11,562)	(19,096)

Other income and expenses (Tables)

6 Months Ended

Jun. 30, 2020

Other income and expenses

Schedule of other operating income


	For the three months ended June 30		For the six months ended June 30
in EUR k	2019	2020	2019	2020
Government grants	503	703	1,470	1,405
Income from the reversal of provisions	—	—	89	—
Others	87	98	129	341
Total other operating income	590	801	1,688	1,746

Schedule of other operating expenses


	For the three months ended June 30		For the six months ended June 30
in EUR k	2019	2020	2019	2020
Currency losses	—	37	2	37
Expected credit loss allowances on trade receivables	122	500	462	1,674
Others	—	—	—	101
Total other operating expenses	122	537	464	1,812

Trade receivables and contract assets and other assets (Tables)

6 Months Ended

Jun. 30, 2020

Trade receivables and contract assets and other assets

Summary of trade receivables and contract assets and other assets


in EUR k	Dec 31, 2019	Jun 30, 2020
Non‑current
Other assets - Rental deposits	1,948	1,853
Other assets – Others	-	150
	1,948	2,003
Current
Trade receivables, net	12,709	12,473
Contract assets, net	3,884	2,510
Receivables due from shareholders	2,766	2,766
Other assets	5,846	5,716
	25,205	23,465
Total non-current and current trade receivables and contract assets and other assets	27,153	25,468

Summary of expected credit loss rate on total gross trade receivables and contract assets


in EUR k	Dec 31, 2019		Jun 30, 2020
Not past due	11,102		10,340
Past due 1-30 days	1,113		1,159
Past due 31-90 days	1,708		1,508
Past due more than 90 days	5,005		5,985
Total Gross amount of trade receivables and contract assets	18,928		18,992

Expected credit loss rate
Not past due	0.3	%	0.6	%
Past due 1-30 days	1.0	%	5.7	%
Past due 31-90 days	1.2	%	7.6	%
Past due more than 90 days	45.4	%	62.9	%
Expected credit loss rate on total gross trade receivables and contract assets	12.3	%	21.3	%

Expected credit loss	2,335		4,009

Financial liabilities (Tables)

6 Months Ended

Jun. 30, 2020

Financial liabilities

Schedule of interest-bearing liabilities


in EUR k	Dec 31, 2019	Jun 30, 2020
Non‑current liabilities
Non‑current portion of secured bank loans	968	567
Municipal loans	610	—
Total non‑current loans	1,578	567
Lease liabilities	18,069	18,948
Total non‑current liabilities	19,647	19,515

Current liabilities
Current portion of secured bank loans	802	802
Other bank loans	—	438
Bank overdrafts	2,636	3,127
Municipal loans	250	—
Total current loans	3,688	4,367
Current portion of lease liabilities	3,635	3,411
Total current liabilities	7,323	7,778

Total non‑current and current liabilities	26,970	27,293

Schedule of outstanding interest-bearing liabilities


					Dec 31, 2019		Jun 30, 2020
		Nominal			Nominal	Carrying	Nominal	Carrying
in EUR k	Currency	interest rate		Maturity	amount	amount	amount	amount
Secured bank loan	EUR	3.95	%	2018‑25	1,770	1,770	1,369	1,369
Other bank loan	USD	1	%	2020-22	—	—	438	438
Municipal loan	EUR	8.25%; plus 1.5% profit-related; 0.75% on losses		2018-23	500	500	—	—
Municipal loan	EUR	8%; plus 1.5% profit-related; 0.75% on losses		2021	360	360	—	—
Bank overdrafts	EUR	4.46	%	2022	476	476	478	478
Bank overdrafts	EUR	3.75	%	Rollover	2,160	2,160	2,346	2,346
Bank overdrafts	EUR	3.59	%	Rollover	—	—	303	303
Lease liabilities	EUR	2.1%-3.5%*, 5.4%-8.9%		2017-31	21,704	21,704	22,359	22,359
Total interest‑bearing financial liabilities					26,970	26,970	27,293	27,293

* represents the incremental borrowing rate of the Group at the commencement of the leases

Schedule of trade payables and other liabilities


in EUR k	Dec 31, 2019	Jun 30, 2020
Trade payables	8,554	8,828
Government grants (deferred income)	11,289	10,959
Liability for Virtual Stock Option Program	2,769	2,766
Contract liabilities	3,748	3,800
Others	5,258	7,666
Trade payables and other liabilities	31,618	34,019
Non‑current	9,941	9,575
Current	21,677	24,444

General company information (Details) - Follow-on public offering - Common shares - Major purchases of assets € / shares in Units, € in Millions			1 Months Ended
	Jul. 14, 2020 $ / shares	Jul. 14, 2020 EUR (€) € / shares shares	Jul. 31, 2020 $ / shares	Jul. 31, 2020 EUR (€) € / shares shares
General company information
Number of common shares issued (in shares)		3,500,000		3,500,000
Public offering price (in dollars per share) \| (per share)	$ 14.00	€ 12.71	$ 14.00	€ 12.71
Selling shareholders
General company information
Number of common shares issued (in shares)		1,500,000		1,500,000
Net offering proceeds, after deducting underwriting discounts and commissions \| €		€ 18		€ 18
The Company
General company information
Number of common shares issued (in shares)		2,000,000		2,000,000
Net offering proceeds, after deducting underwriting discounts and commissions \| €		€ 24		€ 24

Effect of COVID-19 Pandemic (Details) - EUR (€) € in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Apr. 30, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Infrequent items
Revenues		€ 9,343	€ 10,865	€ 21,172	€ 21,256
Total direct costs		6,815	6,114	13,833	12,858
Property Plant And Equipment
Infrequent items
Total investments in COVID-19 testing		1,900		1,900
Laboratory facilities and equipment
Infrequent items
Total investments in COVID-19 testing		2,500		2,500
Right-of-use assets
Infrequent items
Total investments in COVID-19 testing		600		600
Germany \| Laboratory facilities and equipment
Infrequent items
Additions of property plant and equipment	€ 1,800
Diagnostics
Infrequent items
Revenues		5,737	€ 6,638	13,292	€ 13,223
Revenues from COVID-tests \| Diagnostics
Infrequent items
Revenues		2,082		2,095
Total direct costs		1,283		1,360
Total direct costs related to the free of charge tests		424		483
Revenues from COVID-tests \| Diagnostics \| Europe
Infrequent items
Revenues		€ 2,072		€ 2,085
Revenues from COVID-tests \| Diagnostics \| Germany
Infrequent items
Percentage of revenue				95.00%

Revenues from contracts with customers - Geographical information (Details) - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Disclosure of geographical areas
Rendering of services	€ 9,343	€ 10,865	€ 21,172	€ 21,256
Sales of goods	376	341	652	665
Total Revenues from contracts with external customers	9,719	11,206	21,824	21,921
Europe
Disclosure of geographical areas
Total Revenues from contracts with external customers	3,226	2,130	4,887	3,691
Germany
Disclosure of geographical areas
Total Revenues from contracts with external customers	2,115	266	2,207	328
-Netherlands
Disclosure of geographical areas
Total Revenues from contracts with external customers	0		3
Middle East
Disclosure of geographical areas
Total Revenues from contracts with external customers	1,834	3,218	6,252	6,772
-Saudi Arabia
Disclosure of geographical areas
Total Revenues from contracts with external customers	1,106	1,495	4,139	3,182
North America
Disclosure of geographical areas
Total Revenues from contracts with external customers	4,374	4,936	9,497	9,678
-United States
Disclosure of geographical areas
Total Revenues from contracts with external customers	4,365	4,856	9,339	9,329
Latin America
Disclosure of geographical areas
Total Revenues from contracts with external customers	219	681	965	1,319
Asia Pacific
Disclosure of geographical areas
Total Revenues from contracts with external customers	66	241	223	461
Recognized over time
Disclosure of geographical areas
Total Revenues from contracts with external customers	7,812	10,634	19,641	20,675
Recognized at a point in time
Disclosure of geographical areas
Total Revenues from contracts with external customers	1,907	572	2,183	1,246
Pharmaceutical
Disclosure of geographical areas
Rendering of services	3,606	4,227	7,880	8,033
Sales of goods	334	341	610	665
Total Revenues from contracts with external customers	3,940	4,568	8,490	8,698
Pharmaceutical \| Europe
Disclosure of geographical areas
Total Revenues from contracts with external customers	23	247	67	280
Pharmaceutical \| Germany
Disclosure of geographical areas
Total Revenues from contracts with external customers	19	195	38	195
Pharmaceutical \| -Netherlands
Disclosure of geographical areas
Total Revenues from contracts with external customers	0
Pharmaceutical \| Middle East
Disclosure of geographical areas
Total Revenues from contracts with external customers	45	29	48	61
Pharmaceutical \| North America
Disclosure of geographical areas
Total Revenues from contracts with external customers	3,872	4,292	8,375	8,357
Pharmaceutical \| -United States
Disclosure of geographical areas
Total Revenues from contracts with external customers	3,872	4,292	8,375	8,357
Pharmaceutical \| Asia Pacific
Disclosure of geographical areas
Total Revenues from contracts with external customers	0
Pharmaceutical \| Recognized over time
Disclosure of geographical areas
Total Revenues from contracts with external customers	3,606	3,996	7,880	7,452
Pharmaceutical \| Recognized at a point in time
Disclosure of geographical areas
Total Revenues from contracts with external customers	334	572	610	1,246
Diagnostics
Disclosure of geographical areas
Rendering of services	5,737	6,638	13,292	13,223
Sales of goods	42		42
Total Revenues from contracts with external customers	5,779	6,638	13,334	13,223
Diagnostics \| Europe
Disclosure of geographical areas
Total Revenues from contracts with external customers	3,204	1,883	4,820	3,411
Diagnostics \| Germany
Disclosure of geographical areas
Total Revenues from contracts with external customers	2,096	71	2,169	133
Diagnostics \| -Netherlands
Disclosure of geographical areas
Total Revenues from contracts with external customers	0		3
Diagnostics \| Middle East
Disclosure of geographical areas
Total Revenues from contracts with external customers	1,789	3,189	6,204	6,711
Diagnostics \| -Saudi Arabia
Disclosure of geographical areas
Total Revenues from contracts with external customers	1,106	1,495	4,139	3,182
Diagnostics \| North America
Disclosure of geographical areas
Total Revenues from contracts with external customers	501	644	1,122	1,321
Diagnostics \| -United States
Disclosure of geographical areas
Total Revenues from contracts with external customers	493	564	964	972
Diagnostics \| Latin America
Disclosure of geographical areas
Total Revenues from contracts with external customers	219	681	965	1,319
Diagnostics \| Asia Pacific
Disclosure of geographical areas
Total Revenues from contracts with external customers	66	241	223	461
Diagnostics \| Recognized over time
Disclosure of geographical areas
Total Revenues from contracts with external customers	4,206	€ 6,638	11,761	€ 13,223
Diagnostics \| Recognized at a point in time
Disclosure of geographical areas
Total Revenues from contracts with external customers	€ 1,573		€ 1,573

Revenue from contracts with customers - Additional Information (Details) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020 EUR (€) customer	Jun. 30, 2019 EUR (€)	Jun. 30, 2020 EUR (€) customer	Jun. 30, 2019 EUR (€)
Revenue from contracts with customers
Revenue from contracts with customers	€ 9,719	€ 11,206	€ 21,824	€ 21,921
Provision for expected credit losses on contract assets	€ 500	€ 122	€ 1,674	€ 462
Pharmaceutical Partner
Revenue from contracts with customers
Number of customer in group \| customer	1		1
Revenue contributed by one pharmaceutical partner, as a percentage of Group's total revenues	26.20%	26.70%	26.40%	27.10%
Revenue from contracts with customers	€ 0	€ 80	€ 0	€ 430

Segment information - Information by operating segments (Details) - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Segment information
Rendering of services	€ 9,343	€ 10,865	€ 21,172	€ 21,256
Sales of goods	376	341	652	665
Total Revenues from contracts with external customers	9,719	11,206	21,824	21,921
Adjusted EBITDA	(7,420)	(2,438)	(12,437)	(3,303)
Additions to property, plant and equipment and right-of-use assets	3,623	399	5,027	840
Additions to intangible assets	2,774	2,003	3,965	3,116
Other segment information
Depreciation and amortization	2,348	1,453	4,432	2,849
Research and development expenses	3,119	2,407	5,810	4,108
Pharmaceutical
Segment information
Rendering of services	3,606	4,227	7,880	8,033
Sales of goods	334	341	610	665
Total Revenues from contracts with external customers	3,940	4,568	8,490	8,698
Diagnostics
Segment information
Rendering of services	5,737	6,638	13,292	13,223
Sales of goods	42		42
Total Revenues from contracts with external customers	5,779	6,638	13,334	13,223
Operating segment \| Pharmaceutical
Segment information
Total Revenues from contracts with external customers	3,940	4,568	8,490	8,698
Adjusted EBITDA	1,799	3,217	4,407	6,161
Additions to property, plant and equipment and right-of-use assets	301	172	301	179
Additions to intangible assets	1,852	1,018	2,854	1,786
Other segment information
Depreciation and amortization	389	257	1,071	513
Operating segment \| Diagnostics
Segment information
Total Revenues from contracts with external customers	5,779	6,638	13,334	13,223
Adjusted EBITDA	(824)	530	(737)	541
Additions to property, plant and equipment and right-of-use assets	2,073	227	2,890	247
Other segment information
Depreciation and amortization	617	561	1,161	1,085
Corporate
Segment information
Adjusted EBITDA	(8,395)	(6,185)	(16,107)	(10,005)
Additions to property, plant and equipment and right-of-use assets	1,249		1,836	414
Additions to intangible assets	922	985	1,111	1,330
Other segment information
Depreciation and amortization	1,342	635	2,200	1,252
Research and development expenses	€ 3,119	€ 2,407	€ 5,810	€ 4,108

Segment information - Reconciliation of segment Adjusted EBITDA to Group Loss for the Period (Details) - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Segment information
Depreciation and amortization	€ (2,348)	€ (1,453)	€ (4,432)	€ (2,849)
Operating loss	(10,104)	(6,085)	(18,262)	(10,980)
Income taxes expenses		11	(129)	(163)
Loss for the period	(10,360)	(6,281)	(19,096)	(11,562)
Operating segment
Segment information
Reportable segment Adjusted EBITDA	975	3,747	3,670	6,702
Reportable segment Adjusted EBITDA after corporate expenses	(7,420)	(2,438)	(12,437)	(3,303)
Operating loss	(10,104)	(6,085)	(18,262)	(10,980)
Financial costs, net	(256)	(207)	(705)	(419)
Income taxes expenses		11	(129)	(163)
Loss for the period	(10,360)	(6,281)	(19,096)	(11,562)
Corporate
Segment information
Corporate expenses	(8,395)	(6,185)	(16,107)	(10,005)
Depreciation and amortization	(1,342)	(635)	(2,200)	(1,252)
Sharebased payment expenses
Segment information
Share-based compensation	(336)	(2,195)	(1,393)	(4,828)
Depreciation and amortization
Segment information
Depreciation and amortization	€ (2,348)	€ (1,453)	€ (4,432)	€ (2,849)

Segment information - Additional information (Details) - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Segment information
Real estate transfer tax expenses		€ 1,200		€ 1,200
Property, plant and equipment	€ 10,784		€ 10,784		€ 8,376
Right-of-use assets.	24,750		24,750		24,932
-United States
Segment information
Property, plant and equipment	368		368		286
Right-of-use assets.	876		876		€ 1,042
Corporate
Segment information
Real estate transfer tax expenses			0	1,200
Follow-on public offering \| Corporate
Segment information
Share issue related cost	€ 173		€ 173
IPO \| Corporate
Segment information
Share issue related cost		€ 109		€ 318

Other income and expenses - Other operating income (Details) - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Other income and expenses
Government grants	€ 703	€ 503	€ 1,405	€ 1,470
Income from the reversal of provisions				89
Others	98	87	341	129
Total other operating income	€ 801	€ 590	€ 1,746	€ 1,688

Other income and expenses - Other operating expenses (Details) - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Other income and expenses
Currency losses	€ 37		€ 37	€ 2
Expected credit loss allowances on trade receivables	500	€ 122	1,674	462
Other			101
Total other operating expenses	€ 537	€ 122	€ 1,812	€ 464

Other income and expenses - LPC GmbH (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Other income and expenses
Non-controlling interest	€ (53)	€ (938)
LPC GmbH
Other income and expenses
Proportion of ownership interest in subsidiary	51.00%
Consideration for disposal of subsidiary	€ 213
Consideration to be paid over time	€ 200
Payment due period (in years)	4 years
Non-controlling interest	€ (268)
Profit/(loss) allocated to non-controlling interest	€ (101)

Sale and Leaseback transaction (Details) - EUR (€) € in Thousands	1 Months Ended	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2019
Sale and Leaseback transaction
Real estate transfer tax expenses		€ 1,200	€ 1,200
Rostock headquarters building
Sale and Leaseback transaction
Disposal of property	€ 22,778

Trade receivables and contract assets and other assets (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Non-current
Other assets-Rental deposits	€ 1,853	€ 1,948
Other assets - Others	150
Trade receivables and contract assets and other assets non-current	2,003	1,948
Current
Trade receivables, net	12,473	12,709
Contract assets, net	2,510	3,884
Receivables due from shareholders	2,766	2,766
Other assets	5,716	5,846
Trade receivables and contract assets and other assets current	23,465	25,205
Total non-current and current trade receivables and contract assets and other assets	25,468	27,153
Credit loss rates in relation to the outstanding trade receivables and contract assets
Cash deposits provided as security for bank loans	500
Berlin Offices
Credit loss rates in relation to the outstanding trade receivables and contract assets
Bank guarantee	257
Trade receivables and contract assets
Credit loss rates in relation to the outstanding trade receivables and contract assets
Financial assets	€ 18,992	€ 18,928
Expected credit loss rate	21.30%	12.30%
Expected credit loss	€ 4,009	€ 2,335
Trade receivables and contract assets \| Not past due
Credit loss rates in relation to the outstanding trade receivables and contract assets
Financial assets	€ 10,340	€ 11,102
Expected credit loss rate	0.60%	0.30%
Trade receivables and contract assets \| Past due 1-30 days
Credit loss rates in relation to the outstanding trade receivables and contract assets
Financial assets	€ 1,159	€ 1,113
Expected credit loss rate	5.70%	1.00%
Trade receivables and contract assets \| Past due 31-90 days
Credit loss rates in relation to the outstanding trade receivables and contract assets
Financial assets	€ 1,508	€ 1,708
Expected credit loss rate	7.60%	1.20%
Trade receivables and contract assets \| Past due more than 90 days
Credit loss rates in relation to the outstanding trade receivables and contract assets
Financial assets	€ 5,985	€ 5,005
Expected credit loss rate	62.90%	45.40%
Minimum
Current
Receivables payment terms	30 days
Maximum
Current
Receivables payment terms	90 days
Other assets
Credit loss rates in relation to the outstanding trade receivables and contract assets
VAT receivables	€ 1,124	€ 1,311
Prepaid expenses	2,150	3,481
Receivables from grants	1,068	409
Other assets \| Follow-on public offering
Credit loss rates in relation to the outstanding trade receivables and contract assets
Costs related to the offering	552	€ 0
Other assets \| Rostock headquarters building
Credit loss rates in relation to the outstanding trade receivables and contract assets
Cash deposits provided as security for bank loans	1,500
Bank guarantee	3,000
Other assets \| Berlin Offices
Non-current
Other assets-Rental deposits	128
Other assets \| Certain plant and machineries
Non-current
Other assets-Rental deposits	191
Other assets \| LPC GmbH
Credit loss rates in relation to the outstanding trade receivables and contract assets
Consideration receivable for the sale of LPC	213
Consideration receivable for the sale of LPC due after one year	€ 150

Cash and short-term deposits (Details) - EUR (€) € in Thousands	Jun. 30, 2020	Dec. 31, 2019
Borrowings
Short term deposits pledged as security	€ 500
Secured bank loan
Borrowings
Short term deposits pledged as security	1,500	€ 1,500
Existing Overdraft facility
Borrowings
Short term deposits pledged as security	2,500	2,500
Maximum borrowing capacity	2,500
Second Overdraft facility
Borrowings
Short term deposits pledged as security	500	€ 0
Maximum borrowing capacity	€ 500

Equity - Capital Reserves (Details) € in Thousands	Jun. 30, 2020 EUR (€)
Capital reserve
Share premium included in capital reserve	€ 90,297

Financial liabilities - Interest-bearing loans (Details) - EUR (€) € in Thousands	Jun. 30, 2020	Dec. 31, 2019
Financial liabilities
Total non-current liabilities	€ 19,515	€ 19,647
Total current liabilities	7,778	7,323
Total non-current and current liabilities	27,293	26,970
Short term deposits pledged as security	500
Total loans
Financial liabilities
Total non-current liabilities	567	1,578
Total current liabilities	4,367	3,688
Secured bank loans
Financial liabilities
Total non-current liabilities	567	968
Total current liabilities	802	802
Short term deposits pledged as security	1,500	1,500
Other bank loans
Financial liabilities
Total current liabilities	438
Total non-current and current liabilities	438
Bank overdrafts
Financial liabilities
Total current liabilities	3,127	2,636
Municipal loans
Financial liabilities
Total non-current liabilities		610
Total current liabilities		250
Lease liabilities
Financial liabilities
Total non-current liabilities	18,948	18,069
Total current liabilities	3,411	3,635
Total non-current and current liabilities	€ 22,359	€ 21,704

Financial liabilities - Conditions and statement of liabilities (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2020	Jun. 30, 2020
Financial liabilities
Nominal amount	€ 26,970		€ 27,293
Carrying amount	26,970		27,293
Financial assets pledged as collateral for liabilities or contingent liabilities			500
Bank overdrafts	476		478
Secured bank loans
Financial liabilities
Financial assets pledged as collateral for liabilities or contingent liabilities	1,500		1,500
Bank overdrafts	€ 2,160		2,346
Secured bank loans with maturity period 2018 To 25
Financial liabilities
Nominal interest rate (as a percent)	3.95%	3.95%
Nominal amount	€ 1,770		1,369
Carrying amount	€ 1,770		€ 1,369
Other bank loans
Financial liabilities
Nominal interest rate (as a percent)	1.00%		1.00%
Nominal amount			€ 438
Carrying amount			438
Lease liabilities
Financial liabilities
Nominal amount	€ 21,704		22,359
Carrying amount	€ 21,704		€ 22,359
Municipal loan, 2021, one
Financial liabilities
Nominal interest rate (as a percent)	8.25%
Nominal interest rate profit (as a percent)	1.50%
Nominal interest rate, on losses (as a percent)	0.75%
Nominal amount	€ 500
Carrying amount	€ 500
Municipal loan, 2022
Financial liabilities
Nominal interest rate (as a percent)	8.00%
Nominal interest rate profit (as a percent)	1.50%
Nominal interest rate, on losses (as a percent)	0.75%
Nominal amount	€ 360
Carrying amount	360
Repayment of Municipal Loans
Financial liabilities
Nominal amount	€ 860
Bank overdrafts, one
Financial liabilities
Nominal interest rate (as a percent)	4.46%		4.46%
Nominal amount	€ 476		€ 478
Carrying amount	€ 476		€ 478
Bank overdrafts, two
Financial liabilities
Nominal interest rate (as a percent)	3.75%		3.75%
Nominal amount	€ 2,160		€ 2,346
Carrying amount	€ 2,160		€ 2,346
Bank overdrafts, three
Financial liabilities
Nominal interest rate (as a percent)			3.59%
Nominal amount			€ 303
Carrying amount			€ 303
Minimum \| Lease liabilities
Financial liabilities
Nominal interest rate (as a percent)	5.40%		5.40%
Nominal interest rate at commencement of leases	2.10%
Maximum \| Lease liabilities
Financial liabilities
Nominal interest rate (as a percent)	8.90%		8.90%
Nominal interest rate at commencement of leases	3.50%
Existing Overdraft facility
Financial liabilities
Financial assets pledged as collateral for liabilities or contingent liabilities	€ 2,500		€ 2,500
Second Overdraft facility
Financial liabilities
Financial assets pledged as collateral for liabilities or contingent liabilities	€ 0		€ 500

Financial liabilities - Trade payables and other liabilities (Details) - EUR (€) € in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Disclosure of reconciliation of liabilities arising from financing activities
Trade payables	€ 8,828		€ 8,554
Government grants (deferred income)	10,959		11,289
Liability for Virtual Stock Option Program	2,766		2,769
Contract liabilities	3,800		3,748
Others	7,666		5,258
Trade payables and other liabilities	34,019		31,618
Non-current	9,575		9,941
Current	24,444		21,677
Grants received for investment in property, plant and equipment	390	€ 341
Personnel related liabilities for vacation and bonuses	2,907		2,264
Liabilities for wage and church tax	527		376
Follow-on public offering
Disclosure of reconciliation of liabilities arising from financing activities
Costs relating to offering	€ 725
IPO
Disclosure of reconciliation of liabilities arising from financing activities
Costs relating to offering			€ 565

Share-based payments - Equity share option 2017 (Equity settled) (Details) - Equity share option 2017 (Equity settled)	6 Months Ended	12 Months Ended
	Jun. 30, 2020 Options € / shares shares	Dec. 31, 2019
Share-based payments
Number of options granted \| Options	805,308
Number of common shares per option granted \| shares	1
Exercise price of share options \| € / shares	€ 0.12
Lock-up period	180 days
Weighted average remaining contractual life of outstanding share options	9 years 6 months	10 years

Share-based payments - Equity share option 2019 (Equity settled) (Details) - Equity share option 2019 (Equity settled) - Member of the supervisory board € / shares in Units, € in Thousands	3 Months Ended	6 Months Ended		12 Months Ended
	Jun. 30, 2020 EUR (€)	Jun. 30, 2020 EUR (€)	Jun. 30, 2019 EUR (€)	Dec. 31, 2019 Options € / shares shares
Share-based payments
Number of options granted \| Options				396,522
Number of common shares per option granted \| shares				1
Exercise price of share options				€ 12.58
Vesting period				3 years
Vesting percentage				33.33%
Weighted average remaining contractual life of outstanding share options				10 years
Weighted average fair value of options outstanding				€ 9.08
Share-based payment expense \| €	€ 336	€ 1,393	€ 4,828

Commitments (Details) - EUR (€) € in Thousands	6 Months Ended	12 Months Ended
Commitments (Details) - EUR (€) € in Thousands	Jun. 30, 2020	Dec. 31, 2019
Lease commitments
Total payment obligation	€ 6,172	€ 802
Rostock headquarters building \| Within one year
Lease commitments
Future lease payments to be made	32
Rostock headquarters building \| Within five years
Lease commitments
Future lease payments to be made	1,218
Rostock headquarters building \| Later than 5 years
Lease commitments
Future lease payments to be made	5,324
Office equipment and storage spaces \| Within one year
Lease commitments
Future lease payments to be made	75	72
Office equipment and storage spaces \| Within five years
Lease commitments
Future lease payments to be made	€ 23	€ 36

Contingent Liabilities (Details) - EUR (€) € in Thousands	Jun. 30, 2020	Nov. 08, 2018
Universitair Medisch Centrum Utrecht
Contingent Liabilities
Dispute amount	€ 1,300	€ 880

Subsequent Event (Details) - Follow-on public offering - Common shares - Major purchases of assets € / shares in Units, € in Millions			1 Months Ended
	Jul. 14, 2020 $ / shares	Jul. 14, 2020 EUR (€) € / shares shares	Jul. 31, 2020 $ / shares	Jul. 31, 2020 EUR (€) € / shares shares
Subsequent Event
Number of common shares issued (in shares)		3,500,000		3,500,000
Public offering price (in dollars per share) \| (per share)	$ 14.00	€ 12.71	$ 14.00	€ 12.71
Selling shareholders
Subsequent Event
Number of common shares issued (in shares)		1,500,000		1,500,000
Net offering proceeds, after deducting underwriting discounts and commissions \| €		€ 18		€ 18
The Company
Subsequent Event
Number of common shares issued (in shares)		2,000,000		2,000,000
Net offering proceeds, after deducting underwriting discounts and commissions \| €		€ 24		€ 24